Testing Glofitamab Combined with Polatuzumab and R-miniCHP for Older Adults with Diffuse Large B-cell or High-Grade B-cell Lymphoma

What this Trial Is About

Researchers are evaluating a treatment approach for older adults with diffuse large B-cell lymphoma DLBCL, high-grade B-cell lymphoma HGBCL, or transformed lymphoma. The study aims to find out if the combination of glofitamab, polatuzumab, and obinutuzumab with standard treatment rituximab, cyclophosphamide, doxorubicin, and prednisone, called R-miniCHP is effective and causes few or mild side effects. This is a Phase 2 clinical trial focused on optimizing frontline therapy for people aged 65 to 80 years, including those considered unfit or frail. Participants will receive two cycles of glofitamab and polatuzumab, followed by an interim PET scan to assess response. If the scan is negative, they will get four cycles of a combination of glofitamab, polatuzumab, and R-miniCHP chemotherapy. If the scan is positive but shows partial response or stable disease, participants will receive six cycles of the combination, with polatuzumab omitted in the last two cycles to maintain the standard number of doses. Medications are given intravenously at specified doses and intervals, including a single dose of obinutuzumab before starting glofitamab. During the study, participants will undergo assessments including imaging scans to measure tumor response, laboratory tests, and health evaluations. Researchers will monitor the complete response rate one year after treatment begins to understand how well the therapy works. The study includes safety monitoring and requires participants to comply with all study procedures. Overall participation lasts until the primary outcome is measured, with visits and treatments scheduled according to the study plan.

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma